Guangdong Taienkang Pharmaceutical Co. Ltd (301263) - Total Assets
Based on the latest financial reports, Guangdong Taienkang Pharmaceutical Co. Ltd (301263) holds total assets worth CN¥2.47 Billion CNY (≈ $360.88 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangdong Taienkang Pharmaceutical Co. Ltd - Total Assets Trend (2019–2025)
This chart illustrates how Guangdong Taienkang Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Guangdong Taienkang Pharmaceutical Co. L for the company's overall valuation and market capitalisation.
Guangdong Taienkang Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Guangdong Taienkang Pharmaceutical Co. Ltd's total assets of CN¥2.47 Billion consist of 46.9% current assets and 53.2% non-current assets. Review Guangdong Taienkang Pharmaceutical Co. L debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.0% |
| Accounts Receivable | CN¥321.06 Million | 13.3% |
| Inventory | CN¥98.81 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥431.41 Million | 17.9% |
| Goodwill | CN¥216.66 Million | 9.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Guangdong Taienkang Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 301263 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Taienkang Pharmaceutical Co. Ltd's current assets represent 46.9% of total assets in 2025, a decrease from 57.3% in 2019.
- Cash Position: Cash and equivalents constituted 24.0% of total assets in 2025, up from 11.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 11.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 17.9% of total assets.
Guangdong Taienkang Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Guangdong Taienkang Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Guangdong Taienkang Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.76 | 7.43 |
| Quick Ratio | 2.01 | 2.47 | 7.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥645.07 Million | CN¥780.07 Million | CN¥1.45 Billion |
Guangdong Taienkang Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Taienkang Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.42 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | CN¥2.42 Billion |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Taienkang Pharmaceutical Co. Ltd's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guangdong Taienkang Pharmaceutical Co. Ltd's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guangdong Taienkang Pharmaceutical Co. Ltd (2019–2025)
The table below shows the annual total assets of Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.42 Billion ≈ $353.72 Million |
+4.60% |
| 2024-12-31 | CN¥2.31 Billion ≈ $338.18 Million |
+3.68% |
| 2023-12-31 | CN¥2.23 Billion ≈ $326.19 Million |
+9.29% |
| 2022-12-31 | CN¥2.04 Billion ≈ $298.46 Million |
+116.63% |
| 2021-12-31 | CN¥941.52 Million ≈ $137.77 Million |
+12.79% |
| 2020-12-31 | CN¥834.75 Million ≈ $122.15 Million |
+22.84% |
| 2019-12-31 | CN¥679.56 Million ≈ $99.44 Million |
-- |
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more